Actinium Pharmaceuticals, Inc. (ATNM)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Actinium Pharmaceuticals, Inc. (ATNM) is down 14.7% since the beginning of the year. At $1 per share, ATNM is trading 40.4% below its 52-week high of $2. Investors who bought $1,000 worth of ATNM shares 5 years ago would now be looking at an investment worth $140.

Actinium Pharmaceuticals, Inc. (ATNM) has returned -14.71% so far this year and -30.95% over the past 12 months. Over the last ten years, ATNM has returned -31.93% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Dec 27, 2012, ATNM's average daily return is +0.05%, while the average monthly return is +1.59%. At this rate, an investment would double in approximately 3.7 years.

Historically, 39% of months were positive and 61% were negative. The best month was Mar 2013 with a return of +293.3%, while the worst month was Aug 2024 at -71.2%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 10 months.

On a daily basis, ATNM closed higher 41% of trading days. The best single day was Mar 18, 2013 with a return of +100.0%, while the worst single day was Aug 5, 2024 at -59.8%.

Actinium Pharmaceuticals, Inc. has an annualized alpha of -1.02%, beta of 0.90, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since December 28, 2012.

• This stock participated in 139.37% of S&P 500 Index downside but only -17.07% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ATNM ranks 22 for risk / return — below 22% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Actinium Pharmaceuticals, Inc. (ATNM) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Actinium Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Actinium Pharmaceuticals, Inc. was 99.75%, occurring on Apr 2, 2026. The portfolio has not yet recovered.

The current Actinium Pharmaceuticals, Inc. drawdown is 99.71%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Actinium Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Actinium Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.